Interstitial Lung Disease clinical trials at University of California Health
19 in progress, 12 open to eligible people
Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
open to eligible people ages 18-85
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease …
at UCLA UCSF
Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
open to eligible people ages 18 years and up
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore…
at UCLA
Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
open to eligible people ages 18 years and up
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the…
at UCLA
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
open to eligible people ages 4 years and up
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex…
at UCSF
FAPI PET for Lung Fibrosis
open to eligible people ages 18 years and up
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic…
at UCLA
Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
at UCLA
Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
open to eligible people ages 18 years and up
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
at UC Davis UC Irvine UCLA
Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
open to eligible people ages 18 years and up
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for…
at UCLA
Dry Powder Inhaled Treprostinil in PH
open to eligible people ages 18-80
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.
at UC Davis UCLA UCSF
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
open to eligible people ages 18-90
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information…
at UCSF
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
open to eligible people ages 18 years and up
This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD). The purpose of this study is to compare whether imaging patterns from high-resolution computed…
at UCLA
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
open to eligible people ages up to 24 years
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic…
at UCSF
Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Sorry, not yet accepting patients
Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment…
at UCLA
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, accepting new patients by invitation only
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
at UC Davis UCLA
Lung Cancer Screening CT for Firefighters
Sorry, not yet accepting patients
Firefighters are at increased risk for cancer due to exposure to carcinogenic substances. Current lung cancer screening guidelines are predominantly based on smoking history and do not take into account high risk occupational exposures such as…
at UCSF
Platform Clinical Study for Conquering Scleroderma
Sorry, not currently recruiting here
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung…
at UCLA
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
at UC Davis UC Irvine UCLA UCSD UCSF
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Sorry, accepting new patients by invitation only
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care…
at UCSF
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Sorry, not currently recruiting here
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other…
at UC Davis UCLA
Our lead scientists for Interstitial Lung Disease research studies include Suzanne Kafaja, MD Augustine Chung, MD John A. Belperio, MD Elizabeth R. Volkmann, MD, MS S. Samuel Weigt, MD Rajan Saggar, MD Jeremie Calais Michele Pham, MD Gabriel Salinas Cisneros, MD Jonathan Goldin, MD.
Last updated: